Introduction: Previous results showed a significant decrease in cocaine-using days among cocaine users treated homeopathic fifty-millesimal (LM) potencies of Opium and Erythroxylum coca, as compared to placebo.Those results might have been biased by low adhesion of crack-cocaine users to treatment, trend that has been observed in clinical trials and practice, usually performed in specialized services.Objectives: to investigate 1) the effectiveness and tolerability of LMpotencies of Opium and Erythroxylum coca for cocaine-related disorders and 2) the effectiveness of a qualified primary care setting in increasing treatment attendance and retention.Methods: A randomized, placebo-controlled, double-blind, crossover clinical trial with twelve-week study duration per patient will be performed.120 participants aged between 18 and 60 years, with Assist score for cocaine between 4 and 26 will be included.Exclusion criterion: urinary benzoylecgonine < 150 ng/mL.Participants will receive verum for 6 weeks followed by placebo for 6 weeks, or vice-versa.Primary endpoint: percentage of reported number of cocaine using days at week 6.Secondary endpoints: percentage of reported number of cocaine using days during participation in the study; percentage of positive benzoylecgonine samples; cocaine craving score, daily craving episodes number, craving episodes mean duration, patient perception of medication action favoring craving reduction (assessed by Minnesota Cocaine Craving Scale); Assist score for cocaine; treatment attendance; retention in treatment; Adverse Events.Discussion: For the first time, this study utilizes a primary care setting as a platform to increase treatment adhesion of cocaine users and assess the effectiveness of homeopathy for cocaine-related disorders.
No takes yet. Share an insight, caveat, or question.
Adler et al. (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: